CorMedix and USRC commenced the real-world evidence study upon outpatient commercial launch in July 2024. The study is designed to demonstrate the impact of the broad use of DefenCath in a real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback